Hoth Therapeutics Advances Preclinical Development of HT-KIT With Altasciences Collaboration for Mast Cell-Derived Cancer Treatment
Overview
- Company: Hoth Therapeutics, Inc.
- Indication: Mast Cell-Derived Cancers
- Drug: HT-KIT
- Trial Phase: Preclinical (N/A for IND-enabling studies)
- Nct ID: Not applicable
Development Update
Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, has achieved significant progress in their preclinical development of HT-KIT, a novel therapeutic candidate targeting the treatment of mast cell-derived cancers. With an already earned FDA Orphan Drug Status, HT-KIT is inching closer to clinical trials.
Collaboration with Altasciences
The ongoing partnership with Altasciences, a full-service provider known for its expertise in preclinical through clinical development, has yielded the completion of bioanalytical method development for HT-KIT. The companies are set to embark on a pivotal study that will assess the bioavailability and pharmacokinetics of HT-KIT using blood and plasma samples from a humanized mouse model study conducted at NC State University.
Research Goals
The aim is to meticulously measure the concentration of HT-KIT in the bloodstream post-administration and evaluate how long it persists. This crucial data will contribute to planning the future IND-enabling studies.
Towards Clinical Application
Hoth Therapeutics is eager to transition HT-KIT from the lab to the clinic where it can have a real-world impact on patients struggling with mast cell-derived cancers. Besides cancer treatment, the therapeutic potential of HT-KIT spans conditions such as skin toxicities due to cancer therapy, anaphylaxis, Alzheimer's Disease, and atopic dermatitis—areas with significant need for novel treatments.
Mission and Vision
Hoth Therapeutics reiterates its commitment to addressing and bridging the treatment gaps in areas where current therapies fall short. By collaborating with Altasciences, they aim to uphold a gold standard in the scientific development process.